Top Story

Fecal immunochemical test a good option for colorectal cancer prevention

October 24, 2016

Noninvasive fecal immunochemical testing is an effective alternative to colonoscopy and stool blood-based screening methods for colorectal cancer screening, according to an opinion article published in the Annals of Internal Medicine.

“Colonoscopy accounts for at least 60% of all [colorectal cancer prevention (CRC)] screening in the United States, despite its greater expense and risk for complications compared with other options,” David S. Weinberg, MD, MSc, from the department of medicine at Fox Chase Cancer Center, and colleagues wrote. “Review of this evidence has prompted national CRC screening programs in Europe, Asia, and elsewhere to emphasize guaiac-based fecal occult blood testing (gFOBT) and, more recently, fecal immunochemical testing (FIT) as the primary screening methods.”

In the Journals Plus

Ibrutinib shows promise for advanced CLL with 17p deletion

October 24, 2016
Ibrutinib induced a high overall response rate and demonstrated a favorable safety profile in patients with relapsed or refractory chronic lymphocytic leukemia with 17p…

How would Clinton or Trump impact the country's health care system?

October 24, 2016
Two separate analyses completed by the Commonwealth Fund and an economist at the Rand Corporation of proposed health care plans from Hillary Clinton and Donald Trump…
In the Journals

Melanoma-associated leukoderma may be misdiagnosed as vitiligo

October 24, 2016
Experts frequently misdiagnosed melanoma-associated leukoderma as vitiligo in a blinded assessment, according to study results recently published in the Journal of the

Fred Hutch/University of Washington Cancer Consortium names executive director

October 24, 2016
Nancy E. Davidson, MD, has been appointed executive director of the Fred Hutch/University of Washington Cancer Consortium. The consortium includes Fred Hutchinson…
More News Headlines »

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Meeting News Coverage

VIDEO: Combination therapy with PD-L1, PARP inhibitors appears effective in patients with ovarian, breast cancer

September 8, 2016
More »
CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today